Replies to post #236530 on Biotech Values

[DewDiligence]

If PFE were going to acquire MYOV, they presumably would've done it two days ago, when the Orgovyx collaboration was announced.

Sumitomo (a/k/a Millennium Pharmaceuticals) could yet make a move.

p.s. MYOV is a popular choice in the 2021 charity contest on Silicon Investor.

[DewDiligence]

MYOV hires new CEO:

https://www.globenewswire.com/news-release/2021/01/04/2152496/0/en/Myovant-Sciences-Appoints-Industry-Veteran-David-Marek-as-Chief-Executive-Officer.html

Mr. Marek is a veteran biopharmaceutical executive with over 30 years of experience in the industry. He brings to Myovant the commercial expertise of a seasoned pharmaceutical executive, the strategic prowess from leading one of the world’s most successful healthcare advertising agencies, as well as the consumer and digital marketing know-how from one of the most popular health information portals, WebMD. Mr. Marek joins Myovant from Axsome Therapeutics where he was chief commercial officer responsible for building out commercial capabilities in preparation for multiple expected launches.

The PR praises outgoing CEO, Lynn Seeley, but it says nothing about her reason for leaving or where she is going.